Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a Massachusetts-based commercial-stage biopharmaceutical company that discovers and commercializes novel therapeutic compounds for underserved diseases.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is among the best growth stocks to invest in for the next 5 years. The General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), David O.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under ...

Controversy over AB Hernandez's participation in girls' sports included rule changes, federal investigations and online threats to the state of California by President Donald Trump.

California transgender athlete AB Hernandez believes it’s “weird” that people were so outraged by Hernandez competing against biological females that they protested multiple high school ...

Dublin, Ireland, June 7, Chainwire – AB DAO announced that its native token AB officially began trading on Binance Alpha—Binance’s early-access, exclusive listing platform. What strategic ...

As of Thursday, June 05, Apellis Pharmaceuticals, Inc.’s APLS share price has surged by 5.43%, which has investors questioning if this is right time to sell.

Captrust Financial Advisors purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund ...

Fintel reports that on May 9, 2025, B of A Securities downgraded their outlook for Apellis Pharmaceuticals (NasdaqGS:APLS) from Buy to Neutral. Analyst Price Forecast Suggests 147.77% Upside As of ...